US drug regulator clears Qnovia’s nicotine inhaler for clinical testing
HQ Team October 7, 2024: The US Food and Drug Administration (FDA)has cleared Qnovia Inc’s nicotine inhaler RespiRx for clinical trial. The US.
Drugs
Health
Pharma